Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.41 |
| ▸ | TGM1 | P22735 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821399 | 0.92 | KMT2A (0.40) | F13A1TGM1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3821308 | 0.89 | CA12 (0.37) | F13A1TGM1CA12CA1CA2 | |
| SCHEMBL3821151 | 0.87 | PARP14 (0.41) | KMT2ASMN1; SMN2THRB | |
| SCHEMBL4415959 | 0.84 | DDX3X (0.34) | F13A1TGM1CA12CA1CA2 | |
| SCHEMBL3816758 | 0.81 | CA12 (0.36) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL3822313 | 0.81 | ALDH1A1 (0.37) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL3820739 | 0.80 | PARP14 (0.40) | KMT2ASMN1; SMN2THRB | |
| SCHEMBL4419177 | 0.78 | CA12 (0.32) | ALDH1A1KMT2AMEN1CA12CA1 | |
| SCHEMBL4414797 | 0.77 | TK1 (0.37) | CA12CA1CA2CA9HPGD | |
| SCHEMBL3136458 | 0.77 | TK2 (0.35) | CA12CA1CA2CA9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-7022851-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-04-04 | — | — | US | disclosed |
| EP-1470114-A4 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2005-05-11 | — | — | EP | disclosed |
| EP-1470114-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | Panagene, Inc. (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030195332-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003062212-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195332-A1 | PNA monomer and precursor | RNGTT, NGLY1, NCL | F13A1 307/4885TGM1 2385/4885ALDH1A1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.